GLP-1 Heart Protection: What the SELECT Trial Proved

The SELECT trial, in one paragraph

SELECT randomized ~17,600 adults with established cardiovascular disease and overweight/obesity — none with diabetes — to semaglutide 2.4 mg or placebo. Result: 20% fewer major cardiovascular events over ~3 years, leading to early benefit signals and an FDA indication for Wegovy to reduce cardiovascular risk. It is the first time an obesity drug proved it saves lives, not just pounds.

Why it's not just weight loss

The benefit curve separated early — before meaningful weight was lost — and wasn't fully explained by kilograms shed. Mechanisms beyond the scale: reduced arterial inflammation, improved endothelial function, blood pressure drops, better lipid profiles, and reduced visceral fat's metabolic signaling. See GLP-1 and belly fat for why visceral fat matters specifically.

What about tirzepatide?

Mounjaro/Zepbound improve the same risk markers — blood pressure, triglycerides, inflammatory markers — and Zepbound gained an indication for obstructive sleep apnea, a cardiovascular comorbidity. The dedicated outcomes data is coming, but cardiologists largely treat cardioprotection as a GLP-1 class effect. Related reading: GLP-1 for sleep apnea, GLP-1 and blood pressure.

Who this changes things for

• Heart disease + obesity, no diabetes — the exact SELECT population; strongest case for treatment
• Post-heart-attack or stent patients — secondary prevention now includes weight pharmacotherapy in guidelines
• High CV risk without events yet — diabetes GLP-1 trials showed benefit here too; weight + risk-factor improvement compounds
• Insurance angle — the CV indication opened coverage arguments for people whose plans exclude "weight loss drugs" — see GLP-1 insurance appeals

Frequently asked questions

Do GLP-1 medications protect the heart?

Yes — SELECT showed 20% fewer major CV events on Wegovy-dose semaglutide in people with heart disease and obesity.

Is the heart benefit from weight loss or the drug itself?

Both — benefit appeared before major weight loss; anti-inflammatory and vascular effects contribute. It's now an FDA-approved CV indication.

Does Ozempic protect your heart if you don't have diabetes?

SELECT studied exactly that population — no diabetes — and showed the 20% benefit. That's what made it practice-changing.

Is Mounjaro/Zepbound heart-protective too?

Presumed class effect; dedicated outcomes data pending. Tirzepatide improves the same risk markers comparably.

Can I take GLP-1 if I have heart disease?

SELECT suggests you may specifically benefit — discuss with your cardiologist. Zepbound also has a sleep-apnea indication relevant to cardiac patients.

Bottom line

GLP-1s crossed the line from weight-loss drugs to cardiovascular drugs. For the SELECT population — heart disease plus excess weight — they are now arguably standard of care, not a lifestyle choice. Compare programs. Related: GLP-1 and kidneys, GLP-1 and fatty liver, Wegovy vs Ozempic.

Related reading

• GLP-1 and kidney protection
• GLP-1 and blood pressure
• GLP-1 for sleep apnea
• GLP-1s for seniors